Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
European Journal of Clinical Microbiology & Infectious Diseases Nov 19, 2017
Dobias J, et al. - Researchers, in this study, assessed the activity of the novel siderophore cephalosporin cefiderocol and comparators against a collection of previously characterized Gram-negative isolates using broth microdilution panels. They recognized that cefiderocol was more active compared to the other drugs tested, with the exception of colistin and tigecycline showing equivalent activity against certain subgroups of bacteria.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries